SCHEMBL3282873

SCHEMBL3282873

CC(C(=O)NC1Cc2cc(Cl)ccc2N(Cc2ccccc2)C1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.50
MTNR1B P49286 2/20 0.50
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.39
TEAD1 P28347 1/20 0.39
BRS3 P32247 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284594 0.81 MTNR1A (0.52) MTNR1AMTNR1BKMT2AALDH1A1GAA
SCHEMBL651178 0.81 MTNR1A (0.60) MTNR1AMTNR1BKMT2AALDH1A1GAA
SCHEMBL3291899 0.77 MTNR1A (0.55) MTNR1AMTNR1BKMT2AALDH1A1GAA
SCHEMBL12667026 0.76 MTNR1A (0.51) MTNR1AMTNR1BTEAD1BRS3P2RX7
SCHEMBL3284241 0.74 MTNR1A (0.50) MTNR1AMTNR1BKMT2AALDH1A1GAA
SCHEMBL3288706 0.74 SIGMAR1 (0.57) MTNR1AMTNR1B
SCHEMBL3283908 0.73 SIGMAR1 (0.56) MTNR1AMTNR1BKMT2AALDH1A1GAA
SCHEMBL3287422 0.73 MTNR1A (0.53) MTNR1AMTNR1BKMT2AALDH1A1GAA
SCHEMBL651552 0.72 MTNR1A (0.51) MTNR1AMTNR1BALDH1A1TEAD1BRS3
SCHEMBL3283249 0.71 MTNR1A (0.53) MTNR1AMTNR1BALDH1A1GAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709647-B2 Tetrahydroquinoline cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-05-04 US claimed
US-7709647-B2 Tetrahydroquinoline cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-05-04 US disclosed
US-20080200459-A1 TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2008-08-21 US disclosed
US-20060160850-A1 Bicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200459-A1 TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, GPR18 MTNR1A 121/4885MTNR1B 44/4885KMT2A 1576/4885
US-20060160850-A1 Bicyclic heterocycles as cannabinoid receptor modulators CNR1, CNR2, GPR18 MTNR1A 319/4885MTNR1B 208/4885KMT2A 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.